Skip to main content
Livermore
Livermore
ZHEN

POINT Biopharma Global Inc.

PNTDelisted Dec 27, 2023
Industry
Pharmaceutical Preparations
SEC CIK
0001811764

POINT Biopharma Global Inc. was delisted on Dec 27, 2023; its insiders filed their last Form 4 on Dec 27, 2023; 126 institutions reported holding it in 13F filings for Q3 2023, worth $411.0M in total; no superinvestor held it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by POINT Biopharma Global Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for POINT Biopharma Global Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for POINT Biopharma Global Inc.
NameTitleLast reported holdingLast filingFilings, past year
Silber Allan CExecutive Chairman0IndirectDec 27, 20230
Lubner David CharlesDirector0Dec 27, 20230
Malik RajeshDirector0Dec 27, 20230
Fleshner Neil E.Chief Medical Officer0IndirectDec 27, 20230
Demers William L.Chief Financial Officer–Dec 27, 20230
Goodman Jonathan R.Director0IndirectDec 27, 20230
Margolin YaelDirector0Dec 27, 20230
McCann Joe A.Chief Executive Officer0IndirectDec 27, 20230
Hogue Gerald L.Director0Dec 27, 20230
Jensen Jessica D.EVP Clinical Development–Dec 27, 20230
Kelly JustynaChief Operating Officer–Dec 27, 20230
Biotechnology Value Fund L POther: Former 10% Owner0Dec 20, 20230
BVF Partners L POther: Former 10% Owner0Dec 20, 20230
BVF IncOther: Former 10% Owner0Dec 20, 20230
Biotechnology Value Fund II LPOther: Former 10% Owner0Dec 20, 20230
Lampert Mark NOther: Former 10% Owner0Dec 20, 20230
Biotechnology Value Trading Fund OS LPOther: Former 10% Owner0Dec 20, 20230
BVF Partners OS Ltd.Other: Former 10% Owner0Dec 20, 20230
BVF I GP LLCOther: Former 10% Owner0Dec 20, 20230
BVF II GP LLCOther: Former 10% Owner0Dec 20, 20230
BVF GP Holdings LLCOther: Former 10% Owner0Dec 20, 20230
Martell Bridget ADirector–Jun 14, 20230
Gottlieb Michael M.Chief Commercial Officer–Jul 8, 20210
Gilmour Margaret E.Director–Jul 8, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Dec 20, 2023 (view filing)6:09 PM ETDec 182 daysBiotechnology Value Fund L P and 9 othersOther: Former 10% OwnerSSaleCommon Stock, $0.0001 par value−17.2M$12.45−$213.7M−100.0%0 after3 lots
Nov 30, 2022 (view filing)Nov 291 dayMcCann Joe A.Chief Executive OfficerPPurchase+2.16K$6.64+$14.3K+0.1%3.62M after
Nov 28, 2022 (view filing)Nov 253 daysHogue Gerald L.DirectorPPurchase+3.66K$6.82+$25.0KNew position3.66K after
Nov 28, 2022 (view filing)Nov 235 daysLubner David CharlesDirectorPPurchase+3.60K$6.85+$24.7KNew position3.60K after
Nov 28, 2022 (view filing)Nov 28Same dayMalik RajeshDirectorPPurchase+3.70K$6.66+$24.6KNew position3.70K after
Nov 23, 2022 (view filing)Nov 212 daysMargolin YaelDirectorPPurchase+1.71K$6.56+$11.2KNew position1.71K after
Nov 21, 2022 (view filing)Nov 183 daysGoodman Jonathan R.DirectorPPurchase+6.00K$6.33+$38.0K+16.7%41.9K after
Nov 21, 2022 (view filing)Nov 17-184 daysSilber Allan CExecutive ChairmanPPurchase+50.0K$6.22+$311.2K+1.2%4.27M after2 lots
May 26, 2022 (view filing)May 251 dayFleshner Neil E.Chief Medical OfficerSSale−564.2K$7.51−$4.24M−15.7%3.02M after